Reported results
- Total revenue was $68 million (or $68,298 thousand) for the third quarter of 2026, compared to $70 million (or $70,445 thousand) for the same period in 2025 under GAAP.
- Product sales were $26 million (or $25,693 thousand) for the third quarter of 2026 under GAAP.
- Licensing, royalties and other revenue were $43 million (or $42,605 thousand) for the third quarter of 2026 under GAAP.
- Research and development expenses were $52 million (or $52,446 thousand) for the third quarter of 2026 under GAAP.
- Selling, general and administrative expenses were $24 million (or $23,645 thousand) for the third quarter of 2026 under GAAP.
- Net loss was $31 million (or $31,376 thousand) for the third quarter of 2026 under GAAP.
Guidance
- Combined R&D and SG&A Expenses Full Year 2026 guidance is $375 - $395 million.
- Non-GAAP Combined R&D and SG&A Expenses Full Year 2026 guidance is $315 - $335 million.
- Nuvaxovid Product Sales Full Year 2026 guidance is $40 - $50 million.
- Adjusted Supply Sales Full Year 2026 guidance is $50 - $60 million.
- Sanofi CIC Milestone Full Year 2026 guidance is $125 million.
- Adjusted Licensing, Royalties and Other Revenue Full Year 2026 guidance is $170 - $180 million.
- Adjusted Total Revenue Full Year 2026 guidance is $385 - $415 million.
Price and volatility reaction
The stock moved -8.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -1.1 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 10.65 | 2026-11-04 |
| Close after release | 9.78 | 2026-11-05 |
| Realised move | -8.2% | close to close |
| 30d ATM IV change | -1.1 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
